Open Access

Impact of SGLT2 inhibitors on CV mortality, HF hospitalizations and clinical stability.

Topic: Heart Failure
Sponsored by Charité Berlin - Supported by an unrestricted educational grant from The Boehringer Ingelheim and Lilly Alliance

Congress Presentation

About the speaker

Professor Milton Packer

Baylor University Medical Center, Dallas (United States of America)
53 presentations
10 followers

5 more presentations in this session

Introduction: SGLT2 inhibitors beyond glycemic control.

Speaker: Doctor S. Zieroth (Winnipeg, CA)

Thumbnail

Renal benefits of SGLT2 inhibitors in HF patients.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Thumbnail

Effects of SGLT2 inhibitors on quality of life in HF.

Speaker: Professor J. Butler (Dallas, US)

Thumbnail

Safety of SGLT2 inhibitors with a focus on genital mycotic infections.

Speaker: Professor G. Filippatos (Athens, GR)

Thumbnail

Conclusion.

Speaker: Professor S. Anker (Berlin, DE)

Thumbnail

Access the full session

SGLT2 inhibition in heart failure: what have we learned so far?

Speakers: Professor M. Packer, Doctor S. Zieroth, Professor F. Zannad, Professor J. Butler, Professor G. Filippatos...
Thumbnail

About the event

Image

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb